{
  "abstract": "Background\n\nIcotrokinra, a targeted oral peptide that precisely blocks the interleukin-23 receptor, is approved to treat adult and pediatric (≥12 years, ≥40 kg) patients with moderate-to-severe plaque psoriasis (PsO).Objective\n\nAssess psoriatic arthritis (PsA)-specific outcomes through Week (W) 16 in a subgroup of phase-3 study participants with moderate-to-severe plaque PsO and self-reported medical history of PsA (PsO+PsA).Methods\n\nPost-hoc analyses pooled data from ICONIC-LEAD and ICONIC-ADVANCE 1 and 2 among PsO+PsA participants randomized to once-daily icotrokinra 200 mg or placebo through W16. PsA-specific outcomes included mean change from baseline and ≥50% improvement in Patient's Global Assessment (PtGA) of PsA disease activity and Patient's Assessment of PsA Pain, and percent change from baseline in modified Nail Psoriasis Severity Index (mNAPSI). P values are nominal.Results\n\nAnalyses included 216 participants (149 icotrokinra, 67 placebo). At W8, icotrokinra-treated participants reported greater improvements vs placebo in PtGA of PsA disease activity (-18.5 vs -4.8; P < 0.001) and PsA Pain (-17.1 vs -4.6; P < 0.001), with improvement sustained at W16 (-19.2 vs -0.8; P < 0.001; -19.5 vs -7.8; P = 0.003). At W16, greater proportions of icotrokinra-treated vs placebo-treated participants achieved ≥50% improvement in PtGA of PsA disease activity (47.0% vs 10.7%; P < 0.001) and PsA Pain (45.5% vs 16.1%; P < 0.001). At W16, icotrokinra improved mNAPSI by 41.6% (vs 118.6% worsening with placebo; P < 0.001). Adverse event rates were similar between icotrokinra and placebo.Conclusions\n\nIcotrokinra demonstrated early, substantial improvements in participant-reported PsA activity and PsA Pain, and nail psoriasis, with a favorable safety profile through W16 in participants with PsO+PsA.",
  "abstract_shown": true,
  "affiliations": [
    "MVLS College Office, Wolfson Medical School Building, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.",
    "Henry Ford Health System, West Bloomfield, MI, USA.",
    "Innovaderm Research, Montreal, QC, Canada.",
    "Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.",
    "Johnson & Johnson, Spring House, PA, USA.",
    "Johnson & Johnson, Horsham, PA, USA.",
    "Drexel University College of Medicine, Philadelphia, PA, USA.",
    "Johnson & Johnson, San Francisco, CA, USA.",
    "Department of Dermatology, University of California Los Angeles, Los Angeles, CA, USA.",
    "Department of Dermatology, and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O'Donnell School of Public Health, Dallas, TX, USA."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Iain B McInnes",
      "orcid": "0000-0002-6462-4280"
    },
    {
      "affs": [
        1
      ],
      "name": "Linda Stein Gold"
    },
    {
      "affs": [
        2
      ],
      "name": "Robert Bissonnette"
    },
    {
      "affs": [
        3
      ],
      "name": "Mark G Lebwohl",
      "orcid": "0000-0002-4705-5303"
    },
    {
      "affs": [
        4
      ],
      "name": "Ofelia Reyes-Servin"
    },
    {
      "affs": [
        4
      ],
      "name": "Joseph Cafone",
      "orcid": "0009-0008-7291-1272"
    },
    {
      "affs": [
        5
      ],
      "name": "Ya-Wen Yang"
    },
    {
      "affs": [
        5,
        6
      ],
      "name": "Soumya D Chakravarty"
    },
    {
      "affs": [
        5
      ],
      "name": "Charles Iaconangelo"
    },
    {
      "affs": [
        4
      ],
      "name": "Shu Li"
    },
    {
      "affs": [
        7
      ],
      "name": "Tasneam Shagroni"
    },
    {
      "affs": [
        5
      ],
      "name": "Karissa Lozenski"
    },
    {
      "affs": [
        8
      ],
      "name": "April W Armstrong"
    },
    {
      "affs": [
        9
      ],
      "name": "Joseph F Merola"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/98474s77vnrq9.bib",
  "cited_by": 0,
  "doi": "10.1177/24755303261494526",
  "fulltext_url": "https://europepmc.org/articles/PMC13677984",
  "id": "98474s77vnrq9",
  "issns": [
    "2475-5303",
    "2475-5311"
  ],
  "landing_url": "https://europepmc.org/article/MED/42898453",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2403|Psoriasis: Treatment and Pathogenesis"
    ]
  ],
  "openalex": "W7222895282",
  "pdf_url": "https://europepmc.org/articles/PMC13677984?pdf=render",
  "pmcid": "PMC13677984",
  "pmid": "42898453",
  "published": "2026-10-18",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/98474s77vnrq9.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:33Z",
      "native_id": "MED:42898453",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42898453"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "openalex:2403|Psoriasis: Treatment and Pathogenesis",
      "subfield": "immunology"
    }
  ],
  "title": "Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials.",
  "title_text": "Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:33Z",
  "url": "https://research.draconitic.com/paper/98474s77vnrq9",
  "venue": "Journal of psoriasis and psoriatic arthritis",
  "versions": []
}